13F Holdings
中文EN

TXG 10x Genomics, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1770787 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.6%
TTM net income YoY12.1%
TTM EPS YoY17.5%
Revenue 3-yr CAGR1.5%
Net income 3-yr CAGR—

Margins

Gross margin71.9%
Operating margin-11.7%
Net margin-10.8%
FCF margin15.2%
EBITDA margin-5.3%

Returns

ROE-8.3%
ROA-6.4%
ROIC (approx.)-17.2%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets21.2%
Debt / equity0.00x
Current ratio5.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.49x
Accruals ratio-16.0%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$642.82M$610.78M$618.73M$516.41M$490.49M
Cost of revenue$198.94M$196.30M$209.41M$120.39M$74.09M
Gross profit$443.88M$414.48M$409.31M$396.02M$416.40M
R&D expense$238.63M$264.70M$270.33M$265.67M$211.75M
SG&A expense$316.13M$344.34M$343.33M$298.30M$257.56M
Operating income-$60.98M-$194.56M-$265.33M-$167.94M-$52.25M
Interest expense$0$4,000$33,000$476,000$866,000
Pretax income-$39.91M-$177.70M-$248.76M-$161.97M-$53.72M
Income tax$3.64M$4.93M$6.34M$4.03M$4.51M
Net income-$43.54M-$182.63M-$255.10M-$166.00M-$58.22M
EBITDA-$24.79M-$158.68M-$229.82M-$142.58M-$31.14M
EPS (basic)-0.35-1.52-2.18-1.46-0.53
EPS (diluted)-0.35-1.52-2.18-1.46-0.53
Weighted avg. shares (diluted)124.75M120.45M117.17M113.86M110.35M
Balance sheet
Cash & equivalents$473.97M$344.07M$359.28M$227.35M$596.07M
Short-term investments$49.44M$49.34M$29.41M$210.24M$0
Receivables$47.01M$87.86M$114.83M$104.21M$85.25M
Inventory$56.34M$83.11M$73.71M$81.63M$59.97M
Current assets$684.45M$584.39M$596.02M$635.03M$747.59M
PP&E, net$226.71M$252.65M$279.57M$289.33M$169.49M
Goodwill$4.51M$4.51M$4.51M$4.51M$4.51M
Intangibles$62.33M$15.67M$16.62M$22.86M$25.40M
Total assets$1.04B$918.64M$965.14M$1.03B$1.02B
Current liabilities$153.45M$117.63M$127.16M$130.96M$110.36M
Total liabilities$245.04M$208.50M$224.10M$223.24M$201.26M
Shareholders' equity$796.33M$710.13M$741.04M$805.74M$817.57M
Shares outstanding127.69M122.29M119.10M115.20M112.51M
Cash flow statement
Operating cash flow$136.05M$6.66M-$15.20M-$33.61M-$21.37M
Capital expenditure$5.93M$12.39M$48.60M$131.66M$101.28M
Free cash flow$130.12M-$5.73M-$63.80M-$165.27M-$122.65M
Investing cash flow-$13.44M-$32.63M$133.49M-$350.89M-$106.73M
Financing cash flow$6.80M$10.91M$13.67M$15.82M$35.30M
Depreciation & amortization$36.20M$35.88M$35.51M$25.37M$21.12M
Stock-based compensation$109.12M$140.75M$166.95M$136.85M$95.96M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.